Persistence of pandemic influenza H1N1 virus in young patients after oseltamivir therapy in the 2009-2010 season: A comparison with seasonal H1N1 with or without H275Y mutation

Journal of Infection and Chemotherapy

Volumn 18, Issue 2, 2012, Pages 180-186

  Kawai, Naoki ^a,b   Ikematsu, Hideyuki ^a,b,c   Iwaki, Norio ^a   Kondou, Kunio ^a   Hirotsu, Nobuo ^a   Kawashima, Takashi ^a   Maeda, Tetsunari ^a   Tanaka, Osame ^a   Doniwa, Ken Ichi ^a   Iwakuni, Osamu ^a   Egashira, Keisuke ^a   Yamaji, Kouzaburo ^a   Kashiwagi, Seizaburo ^a  

^a Japan Physician's Association   (Japan)

^b Kyushu University ^*  (Japan)

^c KYUSHU UNIVERSITY   (Japan)

Author keywords

H275Y mutation; Influenza A(H1N1); Oseltamivir; Viral shedding

Indexed keywords

INFLUENZA VACCINE; OSELTAMIVIR;

ADOLESCENT; ADULT; ARTICLE; ASSAY; CHILD; CONTROLLED STUDY; FEMALE; FEVER; H275Y MUTATION; HUMAN; IC 50; INFLUENZA A (H1N1); INFLUENZA VIRUS A H1N1; MAJOR CLINICAL STUDY; MALE; MUTATION; NA INHIBITION ASSAY; PANDEMIC INFLUENZA; PERSISTENT VIRUS INFECTION; SEASONAL INFLUENZA; SEQUENCE ANALYSIS; SYMPTOM; TREATMENT DURATION; TREATMENT RESPONSE; VIRUS ISOLATION;

EID: 84863321543     PISSN: 1341321X     EISSN: 14377780     Source Type: Journal    
DOI: 10.1007/s10156-011-0314-2     Document Type: Article

References (28)

1. Treanor JJ, Hayden FG, Vrooman PS, Barbarash R, Bettis R, Riff D, et al. Efficacy and safety of the oral neuraminidase inhibitor oseltamivir in treating acute influenza. JAMA. 2000;283:1016-24.
2. Gubareva LV, Kaiser L, Hayden FG. Influenza virus neuraminidase inhibitors. Lancet. 2000;355:827-35.
3. Nicholson KG, Aoki FY, Osterhaus AD, Trottier S, Carewicz O, Mercier CH, et al. Efficacy and safety of oseltamivir in treatment of acute influenza: a randomized controlled trial. Lancet. 2000;355:1845-50.
4. Cooper NJ, Sutton AJ, Abrams KR, Wailoo A, Turner D, Nicholson KG. Effectiveness of neuraminidase inhibitors in treatment and prevention of influenza A and B: systemic review and metaanalyses of randomised controlled trials. BMJ. 2003;326:1235-9.
5. Kawai N, Ikematsu H, Iwaki N, Satoh I, Kawashima T, Maeda T, et al. Factors influencing the effectiveness of oseltamivir and amantadine for the treatment of influenza: a multicenter study from Japan of the 2002-2003 influenza season. Clin Infect Dis. 2005;40:1309-16.
6. Kawai N, Ikematsu H, Iwaki N, Maeda T, Satoh I, Hirotsu N, et al. A comparison of the effectiveness of oseltamivir for the treatment of influenza A and influenza B: a Japanese multicenter study of the 2003-2004 and 2004-2005 influenza seasons. Clin Infect Dis. 2006;43:439-44.
7. Kawai N, Ikematsu H, Iwaki N, Kawashima T, Maeda T, Mitsuoka S, et al. Longer virus shedding in influenza B than in influenza A among outpatients treated with oseltamivir. J Infect. 2007;55:267-72.
8. Collins PJ, Haire LF, Lin YP, Liu J, Russell RJ, Walker PA, et al. Crystal structures of oseltamivir-resistant influenza virus neuraminidase mutants. Nature (Lond). 2008;453:1258-61.
9. Lackenby A, Hungnes O, Dudman SG, Meijer A, Paget WJ, Hay AJ, et al. Emergence of resistance to oseltamivir among influenza A(H1N1) viruses in Europe. Eurosurveillance. 2008;13:1-2.
10. Kawai N, Ikematsu H, Iwaki N, Kondou K, Hirotsu N, Kawashima T, et al. Clinical effectiveness of oseltamivir for influenza A(H1N1) virus with H274Y neuraminidase mutation. J Infect. 2009;59:207-12.
11. Kawai N, Ikematsu H, Hirotsu N, Maeda T, Kawashima T, Tanaka O, et al. Clinical effectiveness of oseltamivir and zanamivir for treatment of influenza A virus subtype H1N1 with the H274Y mutation: a Japanese, multicenter study of the 2007-2008 and 2008-2009 influenza seasons. Clin Infect Dis. 2009;49:1828-35.
12. Kawai N, Ikematsu H, Tanaka O, Matsuura S, Maeda T, Yamauchi S, et al. Comparison of the clinical symptoms and the effectiveness of neuraminidase inhibitors for patients with pandemic influenza H1N1 2009 or seasonal H1N1 influenza in the 2007-2008 and 2008-2009 seasons. J Infect Chemother. 2011;17:375-81.
13. WHO. Update on oseltamivir-resistant pandemic A (H1N1) 2009 influenza virus. Wkly Epidemiol Rec (WER). 2010;85:37-48. http://www.who.int/wer/2010/ wer8506.pdf.
14. Infectious Disease Surveillance Center. Oseltamivir-resistant pandemicA(H1N1) 2009 influenza virus in Japan. 1 October 2010. http://idsc.nih.go.jp/iasr/graph/tamiful09-10.gif (in Japanese).
15. Sy CL, Jung Lee SS, Liu MT, Tsai HC, Chen YS. Rapid emergence of oseltamivir resistance. Emerg Infect Dis. 2010;16:723-5.
16. Memoli MJ, Hrabal RJ, Hassantoufighi A, Eichelberger MC, Taubenberger JK. Rapid selection of oseltamivir- and peramivirresistant pandemic H1N1 virus during therapy in 2 immunocompromised hosts. Clin Infect Dis. 2010;50:1252-5.
17. Mungall BA, Xu X, Klimov A. Surveillance of influenza isolates for susceptibility to neuraminidase inhibitors during the 2000-2002 influenza seasons. Virus Res. 2004;103:195-7.
18. The World Health Organization Global Influenza Program Surveillance Network. Evolution of H5N1 avian influenza viruses in Asia. Emerg Infect Dis. 2005;11:1515-21.
19. Zhou B, Donnelly ME, Scholes DT, St. George K, Hatta M, Kawaoka Y, Wentworth DE. Single reaction genomic amplification accelerates sequencing and vaccine production for classical and swine origin human influenza A viruses. J Virol. 2009;83:10309-13.
20. WHO. Transmission dynamics and impact of pandemic influenza A(H1N1) 2009 virus. Wkly Epidemiol Rec. 2009;46:481-4. (http://www.who.int/wer/2009/wer8446. pdf).
21. Li CC, Wang L, Eng HL, You HL, Chang LS, Tang KS, et al. Correlation of pandemic (H1N1) 2009 viral load with disease severity and prolonged viral shedding in children. Emerg Infect Dis. 2010;16:1265-72.
22. De Serres G, Rouleau I, Hamelin ME, Quach C, Skowronski D, Flamand L, et al. Contagious period for pandemic (H1N1) 2009. Emerg Infect Dis. 2010;16:783-8.
23. Yu H, Liao Q, Yuan Y, Zhou L, Xiang N, Huai Y, et al. Effectiveness of oseltamivir on disease progression and viral RNA shedding in patients with mild pandemic 2009 influenza A H1N1: opportunistic retrospective study of medical charts in China. BMJ. 2010;341:c4779. doi:10.1136/bmj.c4779.
24. Xu R, Ekiert DC, Krause JC, Hai R, Crowe JE Jr, Wilson IA. Structural basis of preexisting immunity to the 2009 H1N1 pandemic influenza virus. Science. 2010;328:357-60.
25. Dawood FS, Jain S, Finelli L, Shaw MW, Lindstrom S, Garten RJ, et al. Emergence of a novel swine-origin influenza A (H1N1) virus in humans. N Engl J Med. 2009;360:2605-15.
26. Greenberg ME, Lai MH, Hartel GF, Wichems CH, Gittleson C, Bennet J, et al. Response to a monovalent 2009 influenza A (H1N1) vaccine. N Engl J Med. 2009;361:2405-13.
27. Abed Y, Baz M, Boivin G. Impact of neuraminidase mutations conferring influenza resistance to neuraminidase inhibitors in the N1 and N2 genetic backgrounds. Antivir Ther. 2006;11:971-6.
28. Park KH, Lee SO, Choi SH, Kim MN, Lee JH, Yi H, et al. Successful salvage therapy with inhaled zanamivir in a patient with peramivir-resistant pandemic influenza A (H1N1) 2009 virus. Scand J Infect Dis. 2011;43:151-5.